Pacira BioSciences
$20.03
20
+$0.05+0.25% Friday 20:00
Statistics
Day High
20.58
Day Low
19.94
52W High
40.16
52W Low
19.34
Volume
973,328
Avg. Volume
1,591,007
Mkt Cap
932.32M
P/E Ratio
15.17
Dividend Yield
-
Dividend
-
Earnings
7MayConfirmed
Expected EPS
0.62
Actual EPS
0.62
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PCRX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Abbvie
ABBV
Mkt Cap304.29B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
AMGEN
AMGN
Mkt Cap177.72B
Merck &
MRK
Mkt Cap318.55B
Novartis
NVS
Mkt Cap232.42B
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Analyst Ratings
43$Average Price Target
The highest estimate is $57.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%
About
Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Show more...
CEO
David M. Stack
Employees
711
Country
US
ISIN
US6951271005
WKN
000A1H68T